CTOs on the Move

Navigate Wellbeing

www.navigatewell.com

 
Navigate is a purpose-driven employee engagement technology company with a nimble and customer-focused approach to helping organizations, with a mission to spark positive change by applying their technological capabilities to the field that enables them to make the most impact: health and wellbeing. For the past 13 years, Navigate has assisted organizations by connecting their business goals, mission and values with tailored wellbeing solutions for their teams. Navigate is headquartered in West Des Moines, IA. Recognized as a Shortlister Top Vendor for Wellness Providers in 2019 and 2020.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.navigatewell.com
  • 140 South 68th Street Suite 2200
    West Des Moines, IA USA 50266
  • Phone: 888.282.0822

Executives

Name Title Contact Details

Similar Companies

Thrifty White Drug Stores

Thrifty White is committed to providing healthcare to small towns and cities in the rural midwest that range from 1,000 to 90,000 in population. In 2003 Thrifty White opened it's first telepharmacy site. This concept allows a trained, certified and

Bunnell

Bunnell is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MedData Research

MedData Research is a Walkersville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SouthLight Healthcare

SouthLight Healthcare is a nonprofit organization that provides outpatient and community-based services for mental health and substance use treatment. They empower the journey through prevention, education, and innovative treatment solutions delivered ...

Furiex

Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.